FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743239763> ?p ?o ?g. }

• W2743239763 endingPage "544" @default.
• W2743239763 startingPage "538" @default.
• W2743239763 abstract "Context Stereotactic body radiotherapy (SBRT) is emerging as a treatment option in patients affected by oligorecurrent prostate cancer disease limited to lymph nodes, a subgroup of patients who would otherwise be treated only with androgen deprivation therapy (ADT). Objective To perform a systematic review of SBRT for oligorecurrent prostate cancer limited to lymph nodes. Evidence acquisition We performed a systematic review of PubMed/Medline in October 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). We searched for studies reporting on biochemical or clinical progression and/or toxicity or complications of SBRT. Reports were excluded if these end points could not be ascertained or separately analyzed, or if insufficient details were provided. Evidence of synthesis A total of 363 patients from nine studies were collected. Of these patients, 211 were treated with SBRT for a total of 270 lymph nodes. With an alpha–beta ratio of 3 Gy, the biologically effective dose in fractionated SBRT was >100 Gy in all studies (range, 88–216 Gy). With a median follow-up of 19.23 mo, local control was achieved in 98.1% of patients. Median progression-free survival (defined as biochemical and/or radiological progression) was 22.5 mo (range, 11–30 mo). Information about ADT during SBRT was available in 281 patients, of whom 114 (40.5%) were on ADT during SBRT, and the duration of hormone therapy ranged from 1 to 17.5 mo. Median ADT-free survival was 32.8 mo (range, 25–44 mo). About toxicity, Common Terminology Criteria for Adverse Events toxicity scale was most used. Acute and/or late grade ≥2 toxicity was reported in only 5.6% of patients, and no patient developed grade 4 toxicity. Conclusions SBRT seems to be promising in lymph node oligorecurrent prostate cancer, although there is a weak level of evidence to support such investigational treatment, which is currently based on retrospective studies of single-institution or pooled experiences. ADT-free survival is an interesting end point, which needs to be investigated. Patient summary We performed a systematic review to assess outcomes and toxicity of stereotactic body radiotherapy (SBRT) for patients affected by oligorecurrent prostate cancer limited to lymph nodes. We concluded that SBRT is a promising therapy in this setting, but it needs to be validated in randomized controlled trials." @default.
• W2743239763 created "2017-08-17" @default.
• W2743239763 creator A5012365497 @default.
• W2743239763 creator A5022031803 @default.
• W2743239763 creator A5045260470 @default.
• W2743239763 creator A5049726510 @default.
• W2743239763 creator A5066165482 @default.
• W2743239763 creator A5083566572 @default.
• W2743239763 creator A5089012331 @default.
• W2743239763 date "2017-12-01" @default.
• W2743239763 modified "2023-09-30" @default.
• W2743239763 title "Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy" @default.
• W2743239763 cites W1900676315 @default.
• W2743239763 cites W1971834606 @default.
• W2743239763 cites W1973530756 @default.
• W2743239763 cites W1988133788 @default.
• W2743239763 cites W1989672749 @default.
• W2743239763 cites W2005501262 @default.
• W2743239763 cites W2022980644 @default.
• W2743239763 cites W2051133253 @default.
• W2743239763 cites W2052770508 @default.
• W2743239763 cites W2058188403 @default.
• W2743239763 cites W2080006760 @default.
• W2743239763 cites W2087199973 @default.
• W2743239763 cites W2103623995 @default.
• W2743239763 cites W2108463536 @default.
• W2743239763 cites W2110429519 @default.
• W2743239763 cites W2112887165 @default.
• W2743239763 cites W2113394230 @default.
• W2743239763 cites W2115092415 @default.
• W2743239763 cites W2122904975 @default.
• W2743239763 cites W2123236404 @default.
• W2743239763 cites W2125551462 @default.
• W2743239763 cites W2127240958 @default.
• W2743239763 cites W2134190251 @default.
• W2743239763 cites W2137314791 @default.
• W2743239763 cites W2154974136 @default.
• W2743239763 cites W2160166879 @default.
• W2743239763 cites W2165631314 @default.
• W2743239763 cites W2170356223 @default.
• W2743239763 cites W2170401524 @default.
• W2743239763 cites W2268596702 @default.
• W2743239763 cites W2274991296 @default.
• W2743239763 cites W2338011264 @default.
• W2743239763 cites W2342476337 @default.
• W2743239763 cites W2405616281 @default.
• W2743239763 cites W2470255787 @default.
• W2743239763 cites W2508622292 @default.
• W2743239763 cites W2511755939 @default.
• W2743239763 cites W4231096603 @default.
• W2743239763 cites W4239059149 @default.
• W2743239763 cites W82069182 @default.
• W2743239763 doi "https://doi.org/10.1016/j.euf.2017.07.006" @default.
• W2743239763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28801240" @default.
• W2743239763 hasPublicationYear "2017" @default.
• W2743239763 type Work @default.
• W2743239763 sameAs 2743239763 @default.
• W2743239763 citedByCount "39" @default.
• W2743239763 countsByYear W27432397632018 @default.
• W2743239763 countsByYear W27432397632019 @default.
• W2743239763 countsByYear W27432397632020 @default.
• W2743239763 countsByYear W27432397632021 @default.
• W2743239763 countsByYear W27432397632022 @default.
• W2743239763 countsByYear W27432397632023 @default.
• W2743239763 crossrefType "journal-article" @default.
• W2743239763 hasAuthorship W2743239763A5012365497 @default.
• W2743239763 hasAuthorship W2743239763A5022031803 @default.
• W2743239763 hasAuthorship W2743239763A5045260470 @default.
• W2743239763 hasAuthorship W2743239763A5049726510 @default.
• W2743239763 hasAuthorship W2743239763A5066165482 @default.
• W2743239763 hasAuthorship W2743239763A5083566572 @default.
• W2743239763 hasAuthorship W2743239763A5089012331 @default.
• W2743239763 hasBestOaLocation W27432397632 @default.
• W2743239763 hasConcept C121608353 @default.
• W2743239763 hasConcept C126322002 @default.
• W2743239763 hasConcept C126838900 @default.
• W2743239763 hasConcept C142724271 @default.
• W2743239763 hasConcept C143998085 @default.
• W2743239763 hasConcept C151730666 @default.
• W2743239763 hasConcept C17744445 @default.
• W2743239763 hasConcept C189708586 @default.
• W2743239763 hasConcept C199539241 @default.
• W2743239763 hasConcept C2777899217 @default.
• W2743239763 hasConcept C2779343474 @default.
• W2743239763 hasConcept C2779473830 @default.
• W2743239763 hasConcept C2779720271 @default.
• W2743239763 hasConcept C2780192828 @default.
• W2743239763 hasConcept C509974204 @default.
• W2743239763 hasConcept C71924100 @default.
• W2743239763 hasConcept C86803240 @default.
• W2743239763 hasConceptScore W2743239763C121608353 @default.
• W2743239763 hasConceptScore W2743239763C126322002 @default.
• W2743239763 hasConceptScore W2743239763C126838900 @default.
• W2743239763 hasConceptScore W2743239763C142724271 @default.
• W2743239763 hasConceptScore W2743239763C143998085 @default.
• W2743239763 hasConceptScore W2743239763C151730666 @default.
• W2743239763 hasConceptScore W2743239763C17744445 @default.
• W2743239763 hasConceptScore W2743239763C189708586 @default.

• next